Genmab A/S announced DARZALEX sales results for the first quarter of 2024. For the quarter, the company reported net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million. Net trade sales were USD 1,464 million in the U.S. and USD 1,228 million in the rest of the world.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,968 DKK | -0.10% | -1.69% | -8.40% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.40% | 18.31B | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.01% | 22.18B | |
-16.67% | 21.2B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B | |
-24.98% | 8.21B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024